House — citation-backed clinical decision support for physicians in India
Medicine, answered.
Evidence attached.
Ask a clinical question. Get a cited answer — built for Indian practice.
Tenecteplase 0.25 mg/kg — now first-line alongside alteplase; single bolus, no infusion AHA/ASA 2026
Thrombectomy out to 24 h in selected patients with clinical–imaging mismatch DAWN · DEFUSE-3
Clopidogrel + aspirin 21 days, then single agent — start within 24 h CHANCE · POINT
EF <40%: start all four pillars early — ARNI · β-blocker · MRA · SGLT2i ESC HF 2021
CHA₂DS₂-VA ≥2 → oral anticoagulation; DOAC preferred over warfarin ESC 2024
Rule in/out NSTE-ACS with the ESC 0 h/1 h hs-troponin algorithm ESC ACS 2023
No SABA-only — every adult needs ICS; preferred reliever is as-needed ICS-formoterol (AIR/MART) GINA 2025
Add ICS to LABA+LAMA after exacerbations when eosinophils ≥100; strongly favoured at ≥300 GOLD 2025
6-month all-oral BPaLM regimen for MDR/RR-TB — adopted by NTEP 2024 NTEP 2024 · WHO 2022
NAFLD is now MASLD (NASH→MASH); FIB-4 first-line fibrosis triage AASLD · EASL 2023
Child-Pugh dose-adjustment across the monographs + 181,194 interaction pairs BNF · Stockley's
Nimesulide + paracetamol — banned fixed-dose combination (hepatotoxicity) CDSCO Gazette 2018
SGLT2 inhibitors recommended in CKD down to eGFR ≥20 — slow progression KDIGO 2024
Estimated by the race-free CKD-EPI 2021 creatinine equation NKF-ASN 2021
Metformin contraindicated below eGFR 30 (don't initiate 30–45); DOACs dose-reduced, not stopped FDA · KDIGO 2024
Every system. One source.
Every claim, cited.
For verified physicians · built for Indian practice